Avicanna (STU:0NN) EBIT per Share : €-0.05 (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Avicanna EBIT per Share?

Avicanna's EBIT per Share for the three months ended in Sep. 2024 was €-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.05.

During the past 3 years, the average EBIT per Share Growth Rate was 46.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 34.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Avicanna's EBIT per Share or its related term are showing as below:

STU:0NN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -622.8 Med: 20 Max: 46.5
Current: 46.5

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Avicanna was 46.50% per year. The lowest was -622.80% per year. And the median was 20.00% per year.

STU:0NN's 3-Year EBIT Growth Rate is ranked better than
86.86% of 837 companies
in the Drug Manufacturers industry
Industry Median: 6.8 vs STU:0NN: 46.50

Avicanna's EBIT for the three months ended in Sep. 2024 was €-0.49 Mil.

Avicanna EBIT per Share Historical Data

The historical data trend for Avicanna's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna EBIT per Share Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.77

-0.76

-0.27

-0.15

-0.07

Avicanna Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.02	-0.01	-0.01	-0.01

Avicanna EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Avicanna's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.559	/	84.708
=	-0.07

Avicanna's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.487	/	100.824
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.05

Avicanna (STU:0NN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Avicanna EBIT per Share Related Terms

Thank you for viewing the detailed overview of Avicanna's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (STU:0NN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AVCNF:USA AVCN:Canada

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Avicanna Headlines

No Headlines